Immunotherapy regimes targeting the immune checkpoint molecules programmed cell death protein 1 (PD-1) and programmed death-ligand 1 (PD-L1, CD274) are showing great promises in treating lung cancers, especially in patients with pretreated advanced NSCLC. The gene discussed is CD274; the disease is lung cancer.